(P022) Proton Therapy on an Incline Beam Line: Acute Toxicity Outcomes in Locally Advanced Breast Cancer Patients

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

These early results demonstrate the feasibility of adjuvant breast cancer treatment with US PT on an IBL. Acute toxicity results appear acceptable. Longer follow-up is needed.

Lisa A. McGee, MD, Molly McGue, Megan Dunn, PhD, Stacey Schmidt, Darren Kaplan, Mark Pankuch, William Hartsell, MD; CDH Proton Center; Proton Collaborative Group

BACKGROUND: Adjuvant radiotherapy for locally advanced breast cancer (LABC) is known to reduce local recurrence. Proton therapy can be used to improve the therapeutic ratio by sparing the dose to adjacent nontargeted tissues, including the heart and lung, in breast cancer patients requiring treatment of comprehensive regional lymphatics, including the internal mammary lymph nodes (IMNs). This retrospective series evaluates the acute toxicity outcomes for LABC patients treated with uniform scanning (US) proton therapy (PT) on an incline beam line (IBL).

METHODS: From September 2011 to May 2014, a total of 35 patients with LABC received adjuvant US PT targeting either the chest wall (n = 25) or intact breast (n = 10) plus comprehensive regional lymphatics, including the IMNs. Patients were treated on the IBL with one of the following techniques: superior and inferior anterior superior oblique (ASO) fields alternated every other day with a superior and inferior en face anterior oblique (AO) field (n = 12), all 4 fields daily (n = 22), or a superior and inferior en face AO field only (n = 1). Patients were simulated in a supine position, immobilized in an alpha cradle with the thorax rotated 30 degrees to approximate an en face angle achieved with the AO fields. Toxicity was prospectively assessed using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) weekly during treatment and at 4 weeks following treatment completion.

Outcomes: Median follow-up was 3 months. A total of 34 women and 1 man were treated with adjuvant US PT for stage I (n = 1), II (n = 7), III (n = 27) LABC; 20 were left-sided, 12 were right-sided, and 3 were bilateral. Of the 25 postmastectomy patients, 14 were reconstructed. Initial fields were planned to 50.4 cobalt gray equivalent (CGE) (n = 33) or 45 CGE (n = 2), with 13 patients having a planned boost of 10 CGE (n = 9), 14 CGE (n = 1), 16 CGE (n = 1), and 20 CGE (n = 1). Median total dose received was 50.51 CGE (range: 45.11–70.36 CGE)

All patients experienced acute radiation dermatitis: grade 1 (n = 8), grade 2 (n = 26), and grade 3 (n = 3). Five patients required a break in treatment, and two patients did not complete their full course of prescribed PT due to skin toxicity. Also, 16 patients experienced grade 1 esophagitis, and 13 patients experienced grade 1 chest wall pain. Two patients experienced skin infection following treatment, requiring antibiotic treatment, which occurred the second week following treatment completion.

CONCLUSIONS: These early results demonstrate the feasibility of adjuvant breast cancer treatment with US PT on an IBL. Acute toxicity results appear acceptable. Longer follow-up is needed.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content